A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Pavlos Msaouel, MD, PhD
Advertisement
Articles by Pavlos Msaouel, MD, PhD
Advertisement
Latest Updated Articles
Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney CancerPublished: July 27th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
3
FDA Approves Revumenib in R/R NPM1-Mutant AML
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
